BioNexus Gene Lab (BGLC) Share-based Compensation (2023 - 2025)
BioNexus Gene Lab's (BGLC) quarterly Share-based Compensation came in at $794770.0 in Q4 2025, up 983.07% quarter-over-quarter from -$90001.0 in Q4 2023.
Powered by 
Analysis
BioNexus Gene Lab (BGLC) Share-based Compensation (2023 - 2025) Analysis & Trends
BioNexus Gene Lab has disclosed Share-based Compensation across 2 years of filings, most recently posting $794770.0 for Q4 2025.
- In Q4 2025, Share-based Compensation changed N/A year-over-year to $794770.0; the TTM figure through Dec 2025 stood at $704769.0 (changed N/A YoY), while the FY2025 annual figure was $794770.0, up 463.67% from the prior year.
- Share-based Compensation came in at $794770.0 for Q4 2025 at BioNexus Gene Lab, up from -$90001.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $794770.0 in Q4 2025 to a low of -$90001.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | W.W. Grainger | 59.81 Bn | 59.22 Bn | 1.98 Bn | 25.00 Mn |
| 2 | Fastenal | 55.76 Bn | 55.56 Bn | 1.06 Bn | 31.00 Mn |
| 3 | Ferguson Enterprises | 42.93 Bn | 42.11 Bn | 2.32 Bn | 183.00 Mn |
| 4 | Reliance | 19.94 Bn | 19.70 Bn | 1.30 Bn | 97.40 Mn |
| 5 | Wesco International | 16.86 Bn | 16.06 Bn | 1.46 Bn | 19.10 Mn |
| 6 | Applied Industrial Technologies | 11.85 Bn | 11.72 Bn | 411.22 Mn | 35.64 Mn |
| 7 | Watsco | 11.80 Bn | 11.33 Bn | 578.93 Mn | 813,000.00 |
| 8 | Avantor | 9.95 Bn | 9.64 Bn | 537.00 Mn | 100,000.00 |
| 9 | Core & Main | 7.66 Bn | 7.51 Bn | 520.00 Mn | 3.00 Mn |
| 10 | BioNexus Gene Lab | 2.60 Mn | -922,180.04 | 12,982.00 | - |